Moderna investors should brace for more whiplash

Even after its latest sharp fall, the drugmaker’s stock price assumes wild successes.

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with ...
24/7 Wall St.

Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher

A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna ...

Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?

Moderna launched its coronavirus vaccine in early pandemic days and saw revenue and stock performance skyrocket. As demand ...

Moderna Named a Top Employer by Science for Twelfth Consecutive Year

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top ...
24/7 Wall St.

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...
CNBC

Biotech stocks are surging. How investors can play the new drug innovation boom

Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains ...

The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

The first Phase 3 data for a custom cancer vaccine has raised questions about whether the potential new treatment is needed.